Immuno-oncology Simulator
Immuno-oncology Simulator™: A QSP Platform Model for Immuno-oncology
Predicting optimal drug combinations and dosing regimens in virtual patients
An immune-oncology QSP model to inform the next stages of development
Certara’s IO SimulatorTM predicts the optimal combinations, dose regimens, and biomarkers in virtual patient populations. Selection of the optimal dosing regime and biomarkers for combination therapy in IO requires quantitative consideration of the longitudinal changes in multiple cell populations involved in the Cancer Immunity Cycle. The challenge is determining the optimal combination of dosing regimens and patient stratification biomarkers for specific indications and tumor phenotypes.
IO Simulator™ is a mechanistic model of the biology underlying the Cancer Immunity Cycle and is delivered in the QSP Designer software. It allows modular development of the compound’s method of action calibrated with pre-clinical data, and integration of this model into the IO Simulator to predict clinical outcomes. Virtual trials with IO SimulatorTM consider tumor heterogeneity and allow predictions of optimal dosing and patient stratification biomarkers for specific indications and tumor phenotypes.
Modules of IO Simulator™
- Tumor, lymph, and blood compartments
- Tumor cells
- T cells
- Dendritic cells
- Macrophages
- NK cells
- Multiple cytokines
Drug Modalities
- mAb
- bsAb
- ADC
- Small molecules
IO Simulator™ is an ideal drug companion model, where data obtained in the pre-clinical or early clinical stages of drug development are used to refine the model and make predictions informing decisions in the next stage.
Meet the Expert
Andrzej Kierzek, VP, QSP R&D
Driving innovation in QSP with 25+ years of expertise in molecular and systems biology, leading a team of 20+ scientists to build cutting-edge models and knowledgebases
Talk to a Certara Expert Today
Learn more about our QSP modeling platform for immuno-oncology
Complete the form to book your no-obligation consultation